Results 271 to 280 of about 29,467 (290)
Some of the next articles are maybe not open access.
Interferon free therapy with direct acting antivirals for HCV
Liver International, 2013AbstractThe current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct‐acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG‐IFN) plus ribavirin (RBV) regimen.
Tarik, Asselah, Patrick, Marcellin
openaire +2 more sources
Direct-acting antiviral treatment for patients with hepatocellular carcinoma
Current Opinion in Gastroenterology, 2018Hepatocellular carcinoma (HCC) affects a significant portion of patients with hepatitis C. The use of direct-acting antiviral (DAA) agents has transformed the disease outcomes in this patient group.Hepatitis C virus (HCV) response to DAAs can be affected by the presence of HCC, whereas DAA therapy may affect the risk of HCC recurrence in patients with ...
Tatyana, Kushner +2 more
openaire +2 more sources
Direct-Acting Antiviral Agents
Clinics in Liver Disease, 2015Tatyana Kushner, Vandana Khungar
openaire +1 more source
Direct-acting antiviral treatment for HCV
The Lancet Infectious Diseases, 2016Stelliana, Goutzamanis +4 more
openaire +2 more sources
Direct-acting antiviral (DAA) actions in treatment-naïve patients
Clinics and Research in Hepatology and Gastroenterology, 2011The introduction of telaprevir (TVR) and boceprevir (BOC), the first approved protease inhibitors against hepatitis C virus (HCV), into clinical practice represented the start of an exciting new era of HCV treatment. In addition to improving sustained virological response (SVR) rates in HCV genotype-1 treatment-naïve patients, these drugs administered ...
openaire +2 more sources
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals
Expert Opinion on PharmacotherapyWith the introduction of highly effective and safe therapies with next-generation direct-acting antivirals (DAAs), that act without interferon, hepatitis C virus (HCV) infection remains the only treatable chronic infectious disease.The review aims to provide an overview of the therapy revolution with a description of specific DAAs, their mechanisms of ...
Krystyna, Dobrowolska +7 more
openaire +2 more sources
Direct-acting antivirals for paediatric HCV: we got there
Nature Reviews Gastroenterology & Hepatology, 2017In a new report, adolescents with genotype 2 or 3 HCV infection who were given sofosbuvir and ribavirin showed a near 100% sustained virologic response. This study is the beginning of a new wave of treatments for paediatric HCV infection, forming part of a global strategy to eradicate viral hepatitis.
openaire +2 more sources
Direct acting antiviral‐induced/exacerbated psoriasis: Addendum!
Dermatologic Therapy, 2019Ayman Abdelmaksoud, Michelangelo Vestita
openaire +2 more sources
Direct-acting antiviral treatment for hepatitis C
The Lancet, 2019Jacinta A, Holmes +2 more
openaire +2 more sources